Medicenna’s MDNA11 Study: A Potential Game-Changer in Cancer Treatment?

Medicenna Therapeutics ((TSE:MDNA)) announced an update on their ongoing clinical study.

Medicenna Therapeutics is conducting a Phase 1/2 clinical study titled A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors. The study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of MDNA11, both as a standalone treatment and in combination with a checkpoint inhibitor, in patients with advanced solid tumors. This study is significant as it explores potential new treatment avenues for various difficult-to-treat cancers.

The intervention being tested is MDNA11, a long-acting recombinant interleukin-2 (rIL-2) albumin fusion, administered intravenously every two weeks. It is tested alone and in combination with Pembrolizumab (KEYTRUDA®), an immune checkpoint inhibitor, to determine the recommended dose for expansion.

The study follows an interventional design with a sequential intervention model, focusing on treatment as the primary purpose. There is no masking involved, meaning all participants and researchers know the treatment being administered.

The study began on September 10, 2021, and is currently recruiting participants. The last update was submitted on July 3, 2025. These dates are crucial as they indicate the study’s progression and timeline for potential results.

This clinical update could influence Medicenna’s stock performance and investor sentiment positively, as successful outcomes may enhance the company’s market position. The involvement of Merck Sharp & Dohme LLC as a collaborator adds industry credibility. Investors should monitor this study’s developments, considering the competitive landscape of cancer therapeutics.

The study is ongoing, with further details available on the ClinicalTrials portal.